de Forni M - Search Results

1

Phase I/II pharmacokinetic study of mitoxantrone by continuous venous infusion in patients with solid tumours and lymphoproliferative diseases.

de Forni M, Lachau S, Huguet F, Canal P, Laurent G, Chevreau C, Roche H, Bugat R. de Forni M, et al. Eur J Cancer. 1991;27(6):735-9. doi: 10.1016/0277-5379(91)90177-f. Eur J Cancer. 1991. PMID: 1829914

2

Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study.

de Forni M, Malet-Martino MC, Jaillais P, Shubinski RE, Bachaud JM, Lemaire L, Canal P, Chevreau C, Carrié D, Soulié P, et al. de Forni M, et al. J Clin Oncol. 1992 Nov;10(11):1795-801. doi: 10.1200/JCO.1992.10.11.1795. J Clin Oncol. 1992. PMID: 1403060 Free article.

3

Teniposide and cisplatin given by intraperitoneal administration: preclinical and phase I/pharmacokinetic studies.

Chatelut E, de Forni M, Canal P, Chevreau C, Roche H, Plusquellec Y, Johnson NP, Houin G, Bugat R. Chatelut E, et al. Among authors: de forni m. Ann Oncol. 1991 Mar;2(3):217-21. doi: 10.1093/oxfordjournals.annonc.a057910. Ann Oncol. 1991. PMID: 2043492 Free article. Clinical Trial.

4

[Cardiotoxicity of continuous intravenous infusion of 5-fluorouracil: clinical study, prevention and physiopathology. Apropos of 13 cases].

de Forni M, Bugat R, Sorbette F, Delay M, Bachaud JM, Chevreau C. de Forni M, et al. Bull Cancer. 1990;77(5):429-38. Bull Cancer. 1990. PMID: 2205312 Review. French.

5

[Continuous double administration of 5 fluorouracil (intravenous and intraperitoneal) modulated by folinic acid: phase I clinical study and pharmacokinetics in patients with intra-abdominal developing cancers].

de Forni M, Gualano V, Canal P, Martel P, Izar-Soum F, Chevreau C, Soulié P, Roché H, Bugat R. de Forni M, et al. Bull Cancer. 1993 May;80(5):408-17. Bull Cancer. 1993. PMID: 8173194 Clinical Trial. French.

6

Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion.

Muller C, Chatelut E, Gualano V, De Forni M, Huguet F, Attal M, Canal P, Laurent G. Muller C, et al. Among authors: de forni m. Cancer Chemother Pharmacol. 1993;32(5):379-84. doi: 10.1007/BF00735923. Cancer Chemother Pharmacol. 1993. PMID: 8339389

7

Human pharmacokinetics of N-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities.

Canal P, Robert J, Ramon M, Baurain R, Tresca P, de Forni M, Marty M, Pujade-Lauraine E, Bugat R, Magis A, et al. Canal P, et al. Among authors: de forni m. Clin Pharmacol Ther. 1992 Mar;51(3):249-59. doi: 10.1038/clpt.1992.19. Clin Pharmacol Ther. 1992. PMID: 1544285 Clinical Trial.

8

Chronopharmacokinetics of doxorubicin in patients with breast cancer.

Canal P, Sqall A, de Forni M, Chevreau C, Pujol A, Bugat R, Roche H, Oustrin J, Houin G. Canal P, et al. Among authors: de forni m. Eur J Clin Pharmacol. 1991;40(3):287-91. doi: 10.1007/BF00315211. Eur J Clin Pharmacol. 1991. PMID: 2060566 Clinical Trial.

9

Clinical and pharmacokinetic study of intraperitoneal cisplatin at two dose levels: 100 mg/m2 alone or 200 mg/m2 with i.v. sodium thiosulfate.

Canal P, de Forni M, Chatelut E, Chevreau C, Johnson NP, Houin G, Bugat R. Canal P, et al. Among authors: de forni m. Acta Med Austriaca. 1989;16(3-4):84-6. Acta Med Austriaca. 1989. PMID: 2609919

10

[Comparison of the pharmacokinetics of cisplatin administered by the intraperitoneal route in 2 dosages: 100 and 200 mg/m2].

Canal P, Chatelut E, De Forni M, Chevreau C, Johnson N, Houin G, Bugat R. Canal P, et al. Among authors: de forni m. Bull Cancer. 1989;76(8):879-82. Bull Cancer. 1989. PMID: 2620116 French. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

44 results

Search Page

Filters